ADTX - Aditxt, Inc.
1.84
-0.240 -13.043%
Share volume: 190,750
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$2.08
-0.24
-0.12%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-20-2024 | 08-14-2023 | 11-14-2023 | 11-18-2024 | 05-20-2024 | 08-19-2024 | 11-18-2024 | |
| Total revenue | 218.415 K | 220.978 K | 124.486 K | 81.297 K | 79.680 K | 44.276 K | 6.854 K | |
| Cost of revenue | 178.309 K | 185.738 K | 106.922 K | 285.867 K | 65.799 K | 23.134 K | 467.536 K | |
| Gross profit | 40.106 K | 35.240 K | 17.564 K | -204.570 K | 13.881 K | 21.142 K | -460.682 K | |
| -12.13% | -50.16% | -1,264.71% | 106.79% | 52.31% | -2,278.99% | |||
| Operating expenses | 5.756 M | 4.156 M | 8.069 M | 7.701 M | 11.509 M | 5.973 M | 4.210 M | |
| Selling general and admin | 4.369 M | 3.671 M | 7.170 M | 3.397 M | 3.364 M | 4.420 M | 3.719 M | |
| Research and development | 1.388 M | 484.835 K | 898.724 K | 4.303 M | 8.145 M | 1.553 M | 491.552 K | |
| Total expenses | 5.822 M | 4.270 M | 8.113 M | 7.746 M | 11.550 M | 5.997 M | 4.240 M | |
| -26.66% | 90.01% | -4.52% | 49.10% | -48.07% | -29.29% | |||
| Operating income | -5.782 M | -4.234 M | -8.095 M | -7.951 M | -11.536 M | -5.976 M | -4.701 M | |
| Ebit | -5.782 M | -4.234 M | -8.095 M | -7.951 M | -11.744 M | -5.976 M | -4.701 M | |
| Pretax income | -5.985 M | -5.682 M | -9.746 M | -10.978 M | -14.869 M | -7.624 M | -6.980 M | |
| -5.06% | 71.52% | 12.64% | 35.44% | -48.73% | -8.44% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -5.985 M | -5.682 M | -9.746 M | -10.978 M | -14.869 M | -7.624 M | -6.980 M | |
| 5.06% | -71.52% | -12.64% | -35.44% | 48.73% | 8.44% |
